MX2020007268A - Regimen de dosificacion de siponimod. - Google Patents

Regimen de dosificacion de siponimod.

Info

Publication number
MX2020007268A
MX2020007268A MX2020007268A MX2020007268A MX2020007268A MX 2020007268 A MX2020007268 A MX 2020007268A MX 2020007268 A MX2020007268 A MX 2020007268A MX 2020007268 A MX2020007268 A MX 2020007268A MX 2020007268 A MX2020007268 A MX 2020007268A
Authority
MX
Mexico
Prior art keywords
siponimod
dosing regimen
stroke
ischemic stroke
crystals
Prior art date
Application number
MX2020007268A
Other languages
English (en)
Inventor
Eric Legangneux
Anne Gardin
Erik Wallström
Jang- Ho Cha
Iii Carl Joseph Malanga
Kasra Shakeri-Nejad
Christian Wolf
Frank Dahlke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020007268A publication Critical patent/MX2020007268A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un nuevo régimen de dosificación para la administración de siponimod o cocristales o sales farmacéuticamente aceptables del mismo, en el tratamiento del accidente cerebrovascular, en particular un accidente cerebrovascular isquémico, por ejemplo, un accidente cerebrovascular isquémico agudo.
MX2020007268A 2017-09-29 2018-09-27 Regimen de dosificacion de siponimod. MX2020007268A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565261P 2017-09-29 2017-09-29
PCT/IB2018/057479 WO2019064212A1 (en) 2017-09-29 2018-09-27 DOSAGE DIAGRAM OF SIPONIMOD

Publications (1)

Publication Number Publication Date
MX2020007268A true MX2020007268A (es) 2020-08-17

Family

ID=63840891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007268A MX2020007268A (es) 2017-09-29 2018-09-27 Regimen de dosificacion de siponimod.

Country Status (11)

Country Link
US (1) US20200316021A1 (es)
EP (1) EP3687530A1 (es)
JP (1) JP2020535147A (es)
KR (1) KR20200062241A (es)
CN (1) CN111107845A (es)
AU (1) AU2018341154A1 (es)
CA (1) CA3073910A1 (es)
IL (1) IL273419A (es)
MX (1) MX2020007268A (es)
RU (1) RU2020114750A (es)
WO (1) WO2019064212A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220144768A1 (en) * 2019-02-27 2022-05-12 Dr. Reddy's Laboratories Limited Solid state forms of siponimod
EP3972954A1 (en) * 2019-05-21 2022-03-30 Synthon B.V. Siponimod maleic acid and fumaric acid salt
WO2021214717A1 (en) * 2020-04-23 2021-10-28 Novartis Ag Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome
JP2024545920A (ja) * 2021-12-31 2024-12-13 ハンジョウ アダメルク ファームラボス インコーポレーテッド 心脳血管薬およびその使用
US20260207513A1 (en) * 2022-12-12 2026-07-23 Synthon B.V. Pharmaceutical composition of siponimod

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
AU2009327405A1 (en) 2008-12-18 2011-06-30 Novartis Ag New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
RU2011129229A (ru) 2008-12-18 2013-01-27 Новартис Аг Новые соли
HRP20131106T1 (hr) 2008-12-18 2013-12-20 Novartis Ag Hemifumaratna sol od 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
MX367667B (es) * 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
SG191286A1 (en) 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
WO2013113915A1 (en) 2012-02-03 2013-08-08 Novartis Ag Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
CN106456552A (zh) * 2014-04-10 2017-02-22 诺华股份有限公司 S1p调节剂的立即释放剂量方案
KR102466348B1 (ko) 2014-04-10 2022-11-10 노파르티스 아게 면역억제제 제제
CA2962922C (en) * 2014-09-29 2021-10-26 The Scripps Research Institute Sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders

Also Published As

Publication number Publication date
AU2018341154A1 (en) 2020-03-12
KR20200062241A (ko) 2020-06-03
CA3073910A1 (en) 2019-04-04
EP3687530A1 (en) 2020-08-05
RU2020114750A (ru) 2021-10-29
IL273419A (en) 2020-05-31
WO2019064212A1 (en) 2019-04-04
US20200316021A1 (en) 2020-10-08
JP2020535147A (ja) 2020-12-03
CN111107845A (zh) 2020-05-05

Similar Documents

Publication Publication Date Title
PH12018500894A1 (en) Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab
JOP20200110A1 (ar) متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
AR103680A1 (es) Inhibidores selectivos de bace1
EA201691741A1 (ru) Фармацевтическая композиция
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
MX2017001487A (es) Sofosbuvir en forma cristalina y proceso para su preparacion.
PH12018500903A1 (en) Pyranodipyridine compound
EA033423B1 (ru) Циклопропанбензофуранилпиридопиразиндионы
IN2014MU00916A (es)
MX2020007326A (es) Regimen de dosificacion de siponimod.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
TN2018000326A1 (en) Granule formulation for oral administration.
PH12016502234A1 (en) Process for obtaining optically active pirlindole enantiomers and salts thereof
MX2020007270A (es) Formulacion parenteral que comprende siponimod.
MD20180049A2 (ro) Compoziţie farmaceutică
TWD186752S (zh) 冷充填瓶
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
EA201790526A1 (ru) Фармацевтические комбинации ситаглиптина
IN2013CH04314A (es)